IGALMI

Class [005]
Pharmaceuticals for the treatment of agitation, namely, an orally-dissolving formulation used for the treatment of agitation associated with alcohol withdrawal, opioid use disorder, opioid withdrawal, substance abuse withdrawal, or other central nervous system disorders, namely, Alzheimer disease, frontotemporal dementia (FTD), dementia, dementia with Lewy bodies (DLB), post-traumatic stress disorder, Parkinson's disease, vascular dementia, vascular cognitive impairment, Huntington's disease, multiple sclerosis, Creutzfeldt-Jakob disease, multiple system atrophy, progressive supranuclear palsy, senile dementia of the Alzheimer type (SDAT), schizophrenia, bipolar disorder, bipolar mania, delirium, depression, major depression, and mood disorders.